Evidence map›Paper›PMID 41299717›Full record

ArticleStem cell research & therapy2025

Extracellular vesicles from Yiguanjian-primed bone-marrow mesenchymal stem cells ameliorate chronic liver fibrosis via miR-7045-5p.

Zhejun Liu, Xiaodan Jiang, Hongjie You, Zuoqing Tang, Yun Ma, Niancong Che, Chongyang Ma, Wenlan Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhejun LiuSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Xiaodan JiangSuzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, Jiangsu, China.
Hongjie YouSchool of Basic Medical Sciences, Capital Medical University, Beijing, China.
Zuoqing TangSchool of Basic Medical Sciences, Capital Medical University, Beijing, China.
Yun MaSchool of Basic Medical Sciences, Capital Medical University, Beijing, China.
Niancong CheSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Chongyang MaSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Wenlan LiuSchool of Traditional Chinese Medicine, Capital Medical University, Beijing, China. Wenlanliu1900@126.com.

Funding

National Natural Science Foundation of China 81573879National Natural Science Foundation of China 82574919Natural Science Foundation of Beijing Municipality 7182021
6 · The paper itself

Abstract

backgroundLiver fibrosis is a crucial pathological stage in the progression of chronic liver diseases. Yiguanjian (YGJ), a Chinese herbal formula, exhibits anti-inflammatory, anti-fibrotic, and hepatoprotective effects. Extracellular vesicles from bone-marrow mesenchymal stem cells (BMSC-EVs) have shown potential in treating various disorders, including liver fibrosis. This study investigated the regulatory effects of EVs from YGJ-preconditioned BMSCs (YGJ-EVs) on TGF-β1-stimulated hepatic stellate cells (HSCs) and their therapeutic potential in a mouse model of liver fibrosis, with a focus on identifying the causative microRNA cargo.

methodsYGJ-EVs and control EVs were isolated from BMSC culture supernatants and characterized via western blotting, transmission electron microscopy, and nanoparticle tracking analysis. Their cellular uptake in vitro and in vivo was evaluated using DIR labeling. To identify candidate miRNAs mediating YGJ-EV bioactivity, miRNA microarray analysis was conducted. To assess the effect of YGJ-EVs on liver fibrosis, TGF-β1-activated HSC cells were treated with YGJ-EVs or control-EVs for 24 h, and then the expression of proteins related to fibrotic activation (COL1-A1 and α-SMA), lysosomal biogenesis (LAMP1, TPP1, CTSD, and CTSB) mitophagy (p62, LC3, PINK1, and Parkin), and the Akt/AMPK/TFEB pathway was assessed. To determine whether miR-7045-5p is the causative factor, HSC cells transfected with miR-7045-5p were similarly analyzed.

resultsmiRNA microarray analysis revealed miR-7045-5p upregulation in YGJ-EVs versus control EVs. In CCl

conclusionYGJ increases miR-7045-5p abundance in BMSC-EVs. YGJ-EVs alleviate liver fibrosis by delivering the anti-fibrotic miRNA miR-7045-5p, which inhibits the Akt/AMPK/TFEB pathway, thereby promoting lysosomal biogenesis and mitophagy in HSCs.

Indexed as

Drugs, Chinese HerbalExtracellular VesiclesLiver CirrhosisMesenchymal Stem CellsMicroRNAsAnimalsDisease Models, AnimalHepatic Stellate CellsMaleMiceMice, Inbred C57BLTransforming Growth Factor beta1Drugs, Chinese HerbalMicroRNAsTransforming Growth Factor beta1Bone marrow mesenchymal stem cellsExtracellular vesiclesLiver fibrosisLysosomal biogenesismiR-7045-5pMitophagy

Identifiers

PMID41299717
PMCPMC12659124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.